CoChat

Fifty years of paracetamol (acetaminophen) poisoning: the development of risk assessment and treatment 1973–2023 with particular focus on contributions published from Edinburgh and Denver

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Fifty years ago, basic scientific studies and the availability of assay methods made the assessment of risk in paracetamol (acetaminophen) poisoning possible. The use of the antidote acetylcysteine linked to new methods of risk assessment transformed the treatment of this poisoning. This review will describe the way in which risk assessment and treatments have developed over the last 50 years and highlight the remaining areas of uncertainty. METHODS: A search of PubMed and its subsidiary databases revealed 1,166 references published in the period 1963-2023 using the combined terms "paracetamol", "poisoning", and "acetylcysteine". Focused searches then identified 170 papers dealing with risk assessment of paracetamol poisoning, 141 with adverse reactions to acetylcysteine and 114 describing different acetylcysteine regimens. To manage the extensive literature, we focused mainly on contributions made by the authors during their time in Edinburgh and Denver. DOSE AND CONCENTRATION RESPONSE: The key relationship between paracetamol dose and toxicity risk was established in 1971 and led to the development of the Rumack-Matthew nomogram from data collected in Edinburgh. MECHANISMS OF TOXICITY: A series of papers on the mechanisms of toxicity were published in 1973, and these showed that paracetamol hepatotoxicity was caused by the formation of a toxic intermediate epoxide metabolite normally detoxified by glutathione but which, in excess, was bound covalently to hepatic enzymes and proteins. An understanding of the relationship between the rate of paracetamol metabolism, paracetamol concentration, and toxic hazard in humans soon followed. ANTIDOTE DEVELOPMENT AND EFFICACY IN PATIENTS: These discoveries were followed by the testing of a range of sulfhydryl-donors in animals and "at risk" patients. Acetylcysteine was developed as the lead intravenous antidote in the United Kingdom. The license holder in the United States refused to make an intravenous formulation. Thus, oral acetylcysteine became the antidote trialed in the United States National Multicenter Study. Intravenous acetylcysteine regimens used initially in the United Kingdom and subsequently in the United States used loading doses of 150 mg/kg over 15 minutes or one hour, 50 mg/kg over four hours, and 100 mg/kg over 16 hours. These regimens were associated with adverse drug reactions (nausea, vomiting and anaphylactoid reactions) and hence, treatment interruption. Newer dosing regimens now give loading doses more slowly. One, the Scottish and Newcastle Anti-emetic Pretreatment protocol, using an acetylcysteine regimen of 100 mg/kg over two hours followed by 200 mg/kg over 10 hours, has been widely adopted in the United Kingdom. A cohort comparison study suggests this regimen has comparable efficacy to standard regimens and offers opportunities for selective higher acetylcysteine dosing. RISK ASSESSMENT AT PRESENTATION: No dose-ranging studies with acetylcysteine were done, and no placebo-controlled studies were performed. Thus, there is uncertainty regarding the optimal dose of acetylcysteine, particularly in patients ingesting very large overdoses of paracetamol. The choice of intervention concentration on the Rumack-Matthew nomogram has important consequences for the proportion of patients treated. The United States National Multicenter Study used a "treatment" line starting at 150 mg/L (992 µmol/L) at 4 hours post overdose, extending to 24 hours with a half-life of 4 hours, now standard there, and subsequently adopted in Australia and New Zealand. In the United Kingdom, the treatment line was initially 200 mg/L (1,323 µmol/L) at 4 hours (the Rumack-Matthew "risk" line). In 2012, the United Kingdom Medicines and Healthcare products Regulatory Agency lowered the treatment line to 100 mg/L (662 µmol/L) at 4 hours for all patients, increasing the number of patients admitted and treated at a high cost. Risk assessment is a key issue for ongoing study, particularly following the development of potential new antidotes that may act in those at greatest risk. The development of biomarkers to assess risk is ongoing but has yet to reach clinical trials. CONCLUSION: Even after 50 years, there are still areas of uncertainty. These include appropriate acetylcysteine doses in patients who ingest different paracetamol doses or multiple (staggered) ingestions, early identification of at-risk patients, and optimal treatment of late presenters.

Overview

Integrity signals

Registry

Crossref · 10.1080/15563650.2023.2293452

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 91 references

Research works printed but not linked: 3

  1. 10.1001/archinte.1981.00340030118021 · doi:10.1001/archinte.1981.00340030118021
  2. Piperno E, Mosher AH, Berssenbrugge DA, et al. Pathophysiology of acetaminophen overdosage toxicity: implications for management. Pediatrics. 1978;62(5 Pt 2 Suppl):880–889.
  3. Waring WS, Pettie JM, Dow MA, et al. Paracetamol appears to protect against N-acetylcysteine-induced anaphylactoid reactions. Clin Toxicol. 2006;44:441–442.

Cited by

See all 25

Metadata

Authors
Bateman, D. N., Dart, R. C., Dear, J. W., Prescott, L. F., & Rumack, B. H.
Affiliations
  • The Queen's Medical Research Institute (GB)
  • Denver Health Medical Center (US)
Corresponding author
Bateman, D. Nicholas
Venue
Clinical Toxicology
Published
2023-12-02
Volume
61
Issue
12
Pages
1020-1031
ISSN
  • 0009-9309 (ISSN-L)
  • 1556-3650
  • 1556-9519
OpenAlex
W4390704606
Cited by
25
References
91
Citations by year
2026: 4 · 2025: 15 · 2024: 6
FWCI
1.71
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Toxicology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Historical and Scientific Studies
Keywords
acetaminophen toxicity, paracetamol, N-acetylcysteine, Rumack-Matthew nomogram, dose-response relationship, glutathione, antidote efficacy, risk assessment, history of toxicology, hepatotoxicity
MeSH terms
Acetaminophen, Acetylcysteine, Antidotes, Antiemetics, Humans, Multicenter Studies as Topic, Risk Assessment, Analgesics, Non-Narcotic, Chemical and Drug Induced Liver Injury, Drug Overdose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fifty years of paracetamol (acetaminophen) poisoning: the development of risk assessment and treatment 1973–2023 with particular focus on contributions published from Edinburgh and Denver. https://app.cochat.ai/papers/10.1080/15563650.2023.2293452
The paper
Bateman, D. N., Dart, R. C., Dear, J. W., Prescott, L. F., & Rumack, B. H. (2023). Fifty years of paracetamol (acetaminophen) poisoning: the development of risk assessment and treatment 1973–2023 with particular focus on contributions published from Edinburgh and Denver. Clinical Toxicology. https://doi.org/10.1080/15563650.2023.2293452

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.